Which has stronger earnings and valuation, ANL or ZLAB?

Adlai Nortye has higher earnings, but lower revenue than Zai Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.88 -$35.53M N/A N/A Zai Lab $460.16M 6.44 -$175.54M -$1.71 N/A

Is ANL or ZLAB more profitable?

Adlai Nortye has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Adlai Nortye's return on equity of 0.00% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Zai Lab -41.86% -27.43% -16.72%

Does the media prefer ANL or ZLAB?

In the previous week, Zai Lab had 9 more articles in the media than Adlai Nortye. MarketBeat recorded 11 mentions for Zai Lab and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Zai Lab's score of 0.75 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BHVN or ANL?

Adlai Nortye has higher revenue and earnings than Biohaven. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Adlai Nortye $5M 102.88 -$35.53M N/A N/A

Is BHVN or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,070.80% -132.67% Adlai Nortye N/A N/A N/A

Does the media favor BHVN or ANL?

In the previous week, Biohaven had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Biohaven and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Biohaven's score of 0.11 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ANL or ZBIO?

Adlai Nortye has higher earnings, but lower revenue than Zenas BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.88 -$35.53M N/A N/A Zenas BioPharma $10M 184.34 -$377.74M -$8.47 N/A

Is ANL or ZBIO more profitable?

Adlai Nortye's return on equity of 0.00% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Zenas BioPharma N/A -99.99% -58.06%

Does the media prefer ANL or ZBIO?

In the previous week, Zenas BioPharma had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Zenas BioPharma and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Zenas BioPharma's score of 0.94 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NBTX or ANL?

Nanobiotix has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 52.40 -$27.11M N/A N/A Adlai Nortye $5M 102.88 -$35.53M N/A N/A

Is NBTX or ANL more profitable?

Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Adlai Nortye N/A N/A N/A

Does the media favor NBTX or ANL?

In the previous week, Nanobiotix had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Nanobiotix and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Nanobiotix's score of 0.73 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, STOK or ANL?

Stoke Therapeutics has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stoke Therapeutics $184.42M 10.96 -$6.89M -$3.34 N/A Adlai Nortye $5M 102.88 -$35.53M N/A N/A

Does the media prefer STOK or ANL?

In the previous week, Stoke Therapeutics had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Stoke Therapeutics and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Stoke Therapeutics' score of 0.15 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adlai Nortye (ANL) Competitors

$12.86 -0.23 (-1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$12.90 +0.04 (+0.35%)

As of 04:13 PM Eastern

Compare

ANL vs. ZLAB, BHVN, ZBIO, NBTX, and STOK

Should you buy Adlai Nortye stock or one of its competitors? Adlai Nortye's main competitors and comparable companies include Zai Lab (ZLAB), Biohaven (BHVN), Zenas BioPharma (ZBIO), Nanobiotix (NBTX), and Stoke Therapeutics (STOK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adlai Nortye compare to Zai Lab?

Adlai Nortye (NASDAQ:ANL) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adlai Nortye presently has a consensus price target of $24.25, indicating a potential upside of 88.57%. Zai Lab has a consensus price target of $40.20, indicating a potential upside of 54.44%. Given Adlai Nortye's higher possible upside, equities research analysts clearly believe Adlai Nortye is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Adlai Nortye has higher earnings, but lower revenue than Zai Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.88	-$35.53M	N/A	N/A
Zai Lab	$460.16M	6.44	-$175.54M	-$1.71	N/A

Adlai Nortye has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Adlai Nortye's return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Zai Lab	-41.86%	-27.43%	-16.72%

Adlai Nortye has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

In the previous week, Zai Lab had 9 more articles in the media than Adlai Nortye. MarketBeat recorded 11 mentions for Zai Lab and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Zai Lab's score of 0.75 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Adlai Nortye beats Zai Lab on 9 of the 15 factors compared between the two stocks.

How does Adlai Nortye compare to Biohaven?

Biohaven (NYSE:BHVN) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Adlai Nortye's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,070.80%	-132.67%
Adlai Nortye	N/A	N/A	N/A

In the previous week, Biohaven had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Biohaven and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Biohaven's score of 0.11 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven presently has a consensus target price of $21.75, indicating a potential upside of 46.22%. Adlai Nortye has a consensus target price of $24.25, indicating a potential upside of 88.57%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Adlai Nortye has higher revenue and earnings than Biohaven.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Adlai Nortye	$5M	102.88	-$35.53M	N/A	N/A

88.8% of Biohaven shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Summary

Adlai Nortye beats Biohaven on 7 of the 13 factors compared between the two stocks.

How does Adlai Nortye compare to Zenas BioPharma?

Adlai Nortye (NASDAQ:ANL) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Zenas BioPharma had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Zenas BioPharma and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Zenas BioPharma's score of 0.94 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Adlai Nortye's return on equity of 0.00% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Zenas BioPharma	N/A	-99.99%	-58.06%

Adlai Nortye has higher earnings, but lower revenue than Zenas BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.88	-$35.53M	N/A	N/A
Zenas BioPharma	$10M	184.34	-$377.74M	-$8.47	N/A

Adlai Nortye has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, indicating that its stock price is 203% less volatile than the broader market.

Adlai Nortye currently has a consensus target price of $24.25, suggesting a potential upside of 88.57%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 51.66%. Given Adlai Nortye's stronger consensus rating and higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

35.2% of Adlai Nortye shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Adlai Nortye beats Zenas BioPharma on 8 of the 13 factors compared between the two stocks.

How does Adlai Nortye compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

In the previous week, Nanobiotix had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Nanobiotix and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Nanobiotix's score of 0.73 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Adlai Nortye	N/A	N/A	N/A

Nanobiotix currently has a consensus target price of $37.33, suggesting a potential downside of 2.19%. Adlai Nortye has a consensus target price of $24.25, suggesting a potential upside of 88.57%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Nanobiotix has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	52.40	-$27.11M	N/A	N/A
Adlai Nortye	$5M	102.88	-$35.53M	N/A	N/A

Summary

Adlai Nortye beats Nanobiotix on 6 of the 11 factors compared between the two stocks.

How does Adlai Nortye compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Adlai Nortye has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Adlai Nortye's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Adlai Nortye	N/A	N/A	N/A

Stoke Therapeutics currently has a consensus target price of $43.00, suggesting a potential upside of 37.34%. Adlai Nortye has a consensus target price of $24.25, suggesting a potential upside of 88.57%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

35.2% of Adlai Nortye shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.96	-$6.89M	-$3.34	N/A
Adlai Nortye	$5M	102.88	-$35.53M	N/A	N/A

In the previous week, Stoke Therapeutics had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Stoke Therapeutics and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Stoke Therapeutics' score of 0.15 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Stoke Therapeutics and Adlai Nortye tied by winning 7 of the 14 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$514.40M	$3.72B	$7.03B	$13.08B
Dividend Yield	N/A	3.76%	2.58%	10.74%
P/E Ratio	N/A	10.40	270.65	25.26
Price / Sales	102.88	1,262.33	641.14	104.62
Price / Cash	N/A	102.94	70.59	50.58
Price / Book	-61.24	18.06	13.24	6.24
Net Income	-$35.53M	-$13.23M	$3.45B	$347.70M
7 Day Performance	-7.08%	2.29%	2.03%	1.92%
1 Month Performance	39.18%	0.79%	1.07%	1.05%
1 Year Performance	679.39%	53.96%	67.58%	19.53%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	2.2258 of 5 stars	$12.86 -1.8%	$24.25 +88.6%	+700.6%	$514.40M	$5M	N/A	127	Positive News
ZLAB Zai Lab	2.5744 of 5 stars	$18.37 -0.6%	$40.00 +117.7%	-25.7%	$2.09B	$453.28M	N/A	1,784	News Coverage Earnings Report Insider Trade Gap Up
BHVN Biohaven	3.482 of 5 stars	$13.62 -0.9%	$21.63 +58.7%	+6.8%	$2.05B	N/A	N/A	239	Earnings Report Analyst Forecast
ZBIO Zenas BioPharma	3.6938 of 5 stars	$31.86 +1.4%	$44.29 +39.0%	+96.8%	$2.01B	N/A	N/A	N/A	News Coverage Earnings Report Gap Down
NBTX Nanobiotix	1.4256 of 5 stars	$39.67 +0.4%	$37.33 -5.9%	+427.1%	$2.01B	$36.87M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. ZLAB, BHVN, ZBIO, NBTX, and STOK

How does Adlai Nortye compare to Zai Lab?

Summary

How does Adlai Nortye compare to Biohaven?

Summary

How does Adlai Nortye compare to Zenas BioPharma?

Summary

How does Adlai Nortye compare to Nanobiotix?

Summary

How does Adlai Nortye compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. ZLAB, BHVN, ZBIO, NBTX, and STOK

How does Adlai Nortye compare to Zai Lab?

Do institutionals & insiders believe in ANL or ZLAB?

Do analysts recommend ANL or ZLAB?

Which has stronger earnings and valuation, ANL or ZLAB?

Is ANL or ZLAB more profitable?

Which has more volatility & risk, ANL or ZLAB?

Does the media prefer ANL or ZLAB?

Summary

How does Adlai Nortye compare to Biohaven?

Is BHVN or ANL more profitable?

Does the media favor BHVN or ANL?

Do analysts rate BHVN or ANL?

Which has preferable valuation and earnings, BHVN or ANL?

Do insiders and institutionals believe in BHVN or ANL?

Which has more risk and volatility, BHVN or ANL?

Summary

How does Adlai Nortye compare to Zenas BioPharma?

Does the media prefer ANL or ZBIO?

Is ANL or ZBIO more profitable?

Which has better earnings and valuation, ANL or ZBIO?

Which has more volatility & risk, ANL or ZBIO?

Do analysts recommend ANL or ZBIO?

Do institutionals and insiders hold more shares of ANL or ZBIO?

Summary

How does Adlai Nortye compare to Nanobiotix?

Do institutionals and insiders hold more shares of NBTX or ANL?

Which has more risk & volatility, NBTX or ANL?

Does the media favor NBTX or ANL?

Is NBTX or ANL more profitable?

Do analysts recommend NBTX or ANL?

Which has preferable earnings & valuation, NBTX or ANL?

Summary

How does Adlai Nortye compare to Stoke Therapeutics?

Is STOK or ANL more profitable?

Do analysts recommend STOK or ANL?

Do institutionals & insiders have more ownership in STOK or ANL?

Which has preferable earnings & valuation, STOK or ANL?

Does the media prefer STOK or ANL?

Which has more volatility and risk, STOK or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools